10X Genomics, Inc. SEC Filings

10x Genomics (TXG) reported Q3 2025 results with revenue of $149.0 million and a net loss of $27.5 million. Gross margin was 67%. Products and services revenue fell 2% year over year as instruments declined 37% to $12.0 million, while consumables rose 1% to $127.9 million and services grew 29% to $8.1 million.

Year-to-date, revenue reached $476.8 million$45.8 million of license and royalty revenue tied to settlements with Vizgen and Bruker, alongside a $49.9 million gain on settlement. Cash, cash equivalents, and marketable securities totaled $482.1 million as of September 30, 2025.

The company closed the Scale Biosciences asset acquisition with $9.2 million cash and $13.5 million in stock (1,099,992 shares), recorded $22.4 million of contingent consideration at fair value, and expects a $20.0 million payment in Q1 2026. A May 2025 restructuring recorded $6.0 million in charges. Management noted revenues are expected to moderately increase sequentially in Q4 2025 and gross margin may fluctuate with mix and non-recurring items.

10x Genomics (TXG) furnished an 8-K announcing quarterly results. The company reported that it issued a press release with financial results for the quarter ended September 30, 2025, and attached it as Exhibit 99.1. The disclosure under Item 2.02 is furnished and not deemed filed under Section 18 of the Exchange Act.

10x Genomics’ Class A common stock trades on Nasdaq under the symbol TXG. The exhibit list includes the press release dated November 6, 2025 and the Inline XBRL cover page file.

Serge Saxonov, Chief Executive Officer and Director of 10x Genomics (TXG), filed a Form 4 reporting a transaction dated 09/12/2025 in which 900 shares of Class A common stock were disposed (code G). After the reported transaction, Mr. Saxonov directly beneficially owns 1,034,817 shares of Class A common stock. The filing also discloses substantial indirect and convertible holdings held in multiple trusts for which he serves as trustee, including convertible Class B shares that can convert into Class A shares and derivative holdings underlying 1,192,040 and 1,750,000 Class A shares as reported. Footnotes identify transfers on July 18, 2025 and several irrevocable trusts (each holding 250,000 shares) for which he is sole trustee, indicating estate or trust structuring of substantial ownership.

Serge Saxonov, who serves as Chief Executive Officer and a director of 10x Genomics, Inc. (TXG), reported a transaction on 08/22/2025 in which 9,348 shares of Class A common stock were sold at a price of $13.787 per share. The filing indicates the sale was made to cover tax withholding obligations related to the vesting of restricted stock units. After the reported transaction, the filing shows 945,892 shares held directly and additional indirect holdings reported as: 27, 89,825, 213,250, and 58,000 shares, each held via trusts for which the reporting person serves as trustee. The Form 4 was signed by an attorney-in-fact on 08/26/2025.

10x Genomics insider sale by CFO Adam Taich, the company's Chief Financial Officer and reporting person, reported a sale of 22,315 shares of Class A Common Stock on 08/22/2025 at a price of $13.787 per share. Following the sale, Mr. Taich beneficially owned 309,273 shares, reported as direct ownership. The filing explains the shares were sold to cover tax withholding obligations arising from the vesting of restricted stock units. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Taich on 08/26/2025.

Benjamin J. Hindson, President and Chief Scientific Officer of 10x Genomics, Inc. (Ticker: TXG), reported a sale of 7,486 shares of Class A common stock on 08/22/2025 at a price of $13.787 per share. The filing states the shares were sold to cover tax withholding obligations arising from the vesting of restricted stock units. After the transaction, Mr. Hindson beneficially owned 440,888 shares, held directly. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Hindson on 08/26/2025. The filing lists Mr. Hindson as both a director and an officer of the issuer.

10x Genomics (TXG) Form 144 notice: The filing reports a proposed sale of 9,228 shares of common stock through Morgan Stanley Smith Barney with an aggregate market value of $123,747.48, and an approximate sale date of 08/22/2025 on NASDAQ. The securities were acquired as a Restricted Stock Unit grant on 08/21/2025 totaling 25,785 shares, with payment characterized as services rendered. The filer discloses one prior sale in the last three months: Serge Saxonov sold 9,343 shares on 05/22/2025 for $77,540.36. The notice includes the required representation that the seller does not possess undisclosed material adverse information about the issuer.

10x Genomics (TXG) filed a Form 144 reporting a proposed sale under Rule 144 of 7,393 shares of common stock with an aggregate market value of $99,140.13, planned on 08/22/2025 on NASDAQ through Morgan Stanley Smith Barney LLC.

The shares were acquired as a Restricted Stock Unit grant from the issuer on 08/21/2025 totaling 20,657 units and paid as services rendered. The filer also sold 7,485 shares on 05/22/2025 for gross proceeds of $62,120.26. The notice includes the standard representation that the selling person is not aware of undisclosed material adverse information.

10x Genomics (TXG) Form 144 notice shows a proposed sale of 22,037 shares of common stock through Morgan Stanley Smith Barney, with an aggregate market value of $295,516.17 and an approximate sale date of 08/22/2025 on NASDAQ. The filing reports the shares were acquired as a Restricted Stock Unit grant on 08/21/2025 with 61,587 units noted as acquired and payment described as Services Rendered. It also discloses a prior sale by the same person of 4,044 shares on 05/22/2025 for gross proceeds of $33,562.37. The filer affirms no undisclosed material adverse information.